{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:52Z","timestamp":1789609132009,"version":"build-2803163510"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12016-021-08859-0","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T13:02:32Z","timestamp":1626526952000},"page":"282-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Current Perspectives on Severe Drug Eruption"],"prefix":"10.1007","volume":"61","author":[{"given":"Jingzhan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8484-2314","authenticated-orcid":false,"given":"Xiaojing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,17]]},"reference":[{"key":"8859_CR1","unstructured":"International drug monitoring: the role of national centres. Report of a WHO meeting (1972). World Health Organization technical report series 498:1\u201325"},{"issue":"7456","key":"8859_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ (Clinical research ed) 329(7456):15\u201319. https:\/\/doi.org\/10.1136\/bmj.329.7456.15","journal-title":"BMJ (Clinical research ed)"},{"issue":"4","key":"8859_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1365-2125.2007.03064.x","volume":"65","author":"K Wester","year":"2008","unstructured":"Wester K, J\u00f6nsson AK, Spigset O, Druid H, H\u00e4gg S (2008) Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 65(4):573\u2013579. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.03064.x","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"8859_CR4","first-page":"1781","volume":"68","author":"MA Riedl","year":"2003","unstructured":"Riedl MA, Casillas AM (2003) Adverse drug reactions: types and treatment options. Am Fam Physician 68(9):1781\u20131790","journal-title":"Am Fam Physician"},{"issue":"1","key":"8859_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00281-015-0540-2","volume":"38","author":"W Hoetzenecker","year":"2016","unstructured":"Hoetzenecker W, N\u00e4geli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, Guenova E, Cozzio A, French LE (2016) Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol 38(1):75\u201386. https:\/\/doi.org\/10.1007\/s00281-015-0540-2","journal-title":"Semin Immunopathol"},{"issue":"10106","key":"8859_CR6","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/s0140-6736(16)30378-6","volume":"390","author":"TA Duong","year":"2017","unstructured":"Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O (2017) Severe cutaneous adverse reactions to drugs. Lancet (London, England) 390(10106):1996\u20132011. https:\/\/doi.org\/10.1016\/s0140-6736(16)30378-6","journal-title":"Lancet (London, England)"},{"issue":"2\u20133","key":"8859_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12016-014-8418-y","volume":"48","author":"VL Yip","year":"2015","unstructured":"Yip VL, Alfirevic A, Pirmohamed M (2015) Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol 48(2\u20133):165\u2013175. https:\/\/doi.org\/10.1007\/s12016-014-8418-y","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"8859_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/aci.0000000000000546","volume":"19","author":"MR Ardern-Jones","year":"2019","unstructured":"Ardern-Jones MR, Mockenhaupt M (2019) Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Curr Opin Allergy Clin Immunol 19(4):283\u2013293. https:\/\/doi.org\/10.1097\/aci.0000000000000546","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"11","key":"8859_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2165\/00002018-200730110-00003","volume":"30","author":"L Valeyrie-Allanore","year":"2007","unstructured":"Valeyrie-Allanore L, Sassolas B, Roujeau JC (2007) Drug-induced skin, nail and hair disorders. Drug Saf 30(11):1011\u20131030. https:\/\/doi.org\/10.2165\/00002018-200730110-00003","journal-title":"Drug Saf"},{"issue":"2","key":"8859_CR10","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1542\/peds.2008-1923","volume":"123","author":"N Levi","year":"2009","unstructured":"Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, Martin E, Kaufman DW, Maison P (2009) Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 123(2):e297-304. https:\/\/doi.org\/10.1542\/peds.2008-1923","journal-title":"Pediatrics"},{"key":"8859_CR11","doi-asserted-by":"publisher","unstructured":"Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.\u00a0J Investig Dermatol 128 (1):35\u201344.https:\/\/doi.org\/10.1038\/sj.jid.5701033","DOI":"10.1038\/sj.jid.5701033"},{"issue":"1","key":"8859_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"B Sassolas","year":"2010","unstructured":"Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H (2010) ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 88(1):60\u201368. https:\/\/doi.org\/10.1038\/clpt.2009.252","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"8859_CR13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/jid.2012.510","volume":"133","author":"P Sekula","year":"2013","unstructured":"Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC (2013) Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 133(5):1197\u20131204. https:\/\/doi.org\/10.1038\/jid.2012.510","journal-title":"J Invest Dermatol"},{"issue":"1","key":"8859_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1665-2681(19)31817-4","volume":"8","author":"MF Amante","year":"2009","unstructured":"Amante MF, Filippini AV, Cejas N, Lendoire J, Imventarza O, Parisi C (2009) Dress syndrome and fulminant hepatic failure induced by lamotrigine. Ann Hepatol 8(1):75\u201377","journal-title":"Ann Hepatol"},{"key":"8859_CR15","doi-asserted-by":"publisher","unstructured":"Sch\u00f6pf E, St\u00fchmer A, Rzany B, Victor N, Zentgraf R, Kapp JF (1991) Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany.\u00a0Arch Dermatol 127(6):839\u2013842. https:\/\/doi.org\/10.1001\/archderm.1991.01680050083008","DOI":"10.1001\/archderm.1991.01680050083008"},{"key":"8859_CR16","doi-asserted-by":"publisher","unstructured":"Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, Touraine R (1987) Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients.\u00a0Arch Dermatol 123(9):1160\u20131165. https:\/\/doi.org\/10.1001\/archderm.123.9.1160","DOI":"10.1001\/archderm.123.9.1160"},{"issue":"2","key":"8859_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","volume":"56","author":"FA Pereira","year":"2007","unstructured":"Pereira FA, Mudgil AV, Rosmarin DM (2007) Toxic epidermal necrolysis. J Am Acad Dermatol 56(2):181\u2013200. https:\/\/doi.org\/10.1016\/j.jaad.2006.04.048","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"8859_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","volume":"7","author":"AT Borchers","year":"2008","unstructured":"Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 7(8):598\u2013605. https:\/\/doi.org\/10.1016\/j.autrev.2008.06.004","journal-title":"Autoimmun Rev"},{"issue":"7","key":"8859_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","volume":"124","author":"P Cacoub","year":"2011","unstructured":"Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC (2011) The DRESS syndrome: a literature review. Am J Med 124(7):588\u2013597. https:\/\/doi.org\/10.1016\/j.amjmed.2011.01.017","journal-title":"Am J Med"},{"key":"8859_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16751","author":"SJ Chung","year":"2020","unstructured":"Chung SJ, Ahn KM, Oh JH, Shim JS, Park HW (2020) Incidence rates of severe cutaneous adverse reactions due to antiseizure medication: a nationwide study using health claims data in Korea. Epilepsia. https:\/\/doi.org\/10.1111\/epi.16751","journal-title":"Epilepsia"},{"key":"8859_CR21","doi-asserted-by":"publisher","unstructured":"Su SC, Hung SI, Fan WL, Dao RL, Chung WH (2016) Severe cutaneous adverse reactions: the pharmacogenomics from research to clinical implementation.\u00a0Int J Cell Sci Mol 17(11).\u00a0https:\/\/doi.org\/10.3390\/ijms17111890","DOI":"10.3390\/ijms17111890"},{"issue":"2","key":"8859_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5415\/apallergy.2015.5.2.68","volume":"5","author":"DV Nguyen","year":"2015","unstructured":"Nguyen DV, Chu HC, Nguyen DV, Phan MH, Craig T, Baumgart K, van Nunen S (2015) HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy 5(2):68\u201377. https:\/\/doi.org\/10.5415\/apallergy.2015.5.2.68","journal-title":"Asia Pac Allergy"},{"issue":"3","key":"8859_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","volume":"68","author":"T Shiohara","year":"2019","unstructured":"Shiohara T, Mizukawa Y (2019) Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergology international\u202f: official journal of the Japanese Society of Allergology 68(3):301\u2013308. https:\/\/doi.org\/10.1016\/j.alit.2019.03.006","journal-title":"Allergology international : official journal of the Japanese Society of Allergology"},{"issue":"2","key":"8859_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000496389","volume":"6","author":"K Hoosen","year":"2019","unstructured":"Hoosen K, Mosam A, Dlova NC, Grayson W (2019) An update on adverse cutaneous drug reactions in HIV\/AIDS. Dermatopathology (Basel, Switzerland) 6(2):111\u2013125. https:\/\/doi.org\/10.1159\/000496389","journal-title":"Dermatopathology (Basel, Switzerland)"},{"issue":"6","key":"8859_CR25","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.jaad.2020.08.006","volume":"83","author":"A Martinez-Lopez","year":"2020","unstructured":"Martinez-Lopez A, Cuenca-Barrales C, Montero-Vilchez T, Molina-Leyva A, Arias-Santiago S (2020) Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: a guide for the dermatologist. J Am Acad Dermatol 83(6):1738\u20131748. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.006","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"8859_CR26","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1248\/bpb.b17-00207","volume":"40","author":"Y Okamoto-Uchida","year":"2017","unstructured":"Okamoto-Uchida Y, Nakamura R, Sai K, Imatoh T, Matsunaga K, Aihara M, Saito Y (2017) Effect of infectious diseases on the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis. Biol Pharm Bull 40(9):1576\u20131580. https:\/\/doi.org\/10.1248\/bpb.b17-00207","journal-title":"Biol Pharm Bull"},{"key":"8859_CR27","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/cmar.s163391","volume":"10","author":"CB Chen","year":"2018","unstructured":"Chen CB, Wu MY, Ng CY, Lu CW, Wu J, Kao PH, Yang CK, Peng MT, Huang CY, Chang WC, Hui RC, Yang CH, Yang SF, Chung WH, Su SC (2018) Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res 10:1259\u20131273. https:\/\/doi.org\/10.2147\/cmar.s163391","journal-title":"Cancer Manag Res"},{"issue":"1","key":"8859_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","volume":"58","author":"S Halevy","year":"2008","unstructured":"Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58(1):25\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2007.08.036","journal-title":"J Am Acad Dermatol"},{"key":"8859_CR29","doi-asserted-by":"publisher","unstructured":"Abou-Taleb DAE, El-Sayed AM, Ghabesha AA, Hassan SB (2020) Severe cutaneous adverse drug reactions: incidence, clinical patterns, causative drugs and modalities of treatment in Assiut University Hospital, Upper Egypt. Dermatol Ther e14176. https:\/\/doi.org\/10.1111\/dth.14176","DOI":"10.1111\/dth.14176"},{"issue":"3","key":"8859_CR30","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.5415\/apallergy.2019.9.e20","volume":"9","author":"DV Nguyen","year":"2019","unstructured":"Nguyen DV, Vidal C, Chu HC, van Nunen S (2019) Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond. Asia Pac Allergy 9(3):e20. https:\/\/doi.org\/10.5415\/apallergy.2019.9.e20","journal-title":"Asia Pac Allergy"},{"issue":"9","key":"8859_CR31","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1111\/jdv.16339","volume":"34","author":"EC Kuijper","year":"2020","unstructured":"Kuijper EC, French LE, Tensen CP, Vermeer MH, Bouwes Bavinck JN (2020) Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). J Eur Acad Dermatol Venereol\u202f: JEADV 34(9):1957\u20131971. https:\/\/doi.org\/10.1111\/jdv.16339","journal-title":"J Eur Acad Dermatol Venereol : JEADV"},{"issue":"4","key":"8859_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11882-018-0778-6","volume":"18","author":"SS Mustafa","year":"2018","unstructured":"Mustafa SS, Ostrov D, Yerly D (2018) Severe cutaneous adverse drug reactions: presentation, risk factors, and management. Curr Allergy Asthma Rep 18(4):26. https:\/\/doi.org\/10.1007\/s11882-018-0778-6","journal-title":"Curr Allergy Asthma Rep"},{"key":"8859_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08812-7","author":"Y Shi","year":"2021","unstructured":"Shi Y, Tang R, Luo F, Li H, Pan Z, Xu G, Yang Y, Zhao Z, Liang A, Wei JF, Piao Y, Chang C, Sun JL, Platts-Mills TAE (2021) The diagnosis and management of allergic reactions caused by Chinese Materia Medica. Clin Rev Allergy Immunol. https:\/\/doi.org\/10.1007\/s12016-020-08812-7","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"8859_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/der.0000000000000422","volume":"29","author":"C Pettit","year":"2018","unstructured":"Pettit C, Massick S, Bechtel M (2018) Cannabidiol-induced acute generalized exanthematous pustulosis. Dermatitis: contact, atopic, occupational, drug 29(6):345\u2013346. https:\/\/doi.org\/10.1097\/der.0000000000000422","journal-title":"Dermatitis : contact, atopic, occupational, drug"},{"key":"8859_CR35","doi-asserted-by":"publisher","unstructured":"Reap LE, Rodd C, Larios J, Marshall M (2019) Hydrochlorothizide-induced acute generalised exanthematous pustulosis presenting with bilateral periorbital impetigo. BMJ Case Reports 12(2). https:\/\/doi.org\/10.1136\/bcr-2017-223528","DOI":"10.1136\/bcr-2017-223528"},{"issue":"3","key":"8859_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.annder.2015.12.012","volume":"143","author":"A Le Guern","year":"2016","unstructured":"Le Guern A, Kerrad I, Oehler E (2016) Severe cutaneous drug reactions to misused griseofulvin: 2 cases. Ann Dermatol Venereol 143(3):219\u2013222. https:\/\/doi.org\/10.1016\/j.annder.2015.12.012","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"8859_CR37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1684\/ejd.2017.3199","volume":"28","author":"S Olivier","year":"2018","unstructured":"Olivier S, De Montjoye L, Tromme I, Baeck M (2018) Two cases of annular acute generalized exanthematous pustulosis induced by terbinafine. Eur J Dermatol: EJD 28(2):236\u2013238. https:\/\/doi.org\/10.1684\/ejd.2017.3199","journal-title":"European journal of dermatology : EJD"},{"issue":"5","key":"8859_CR38","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/j.clbc.2018.06.009","volume":"18","author":"V Sarradin","year":"2018","unstructured":"Sarradin V, Dalenc F, Sibaud V, Tournier E, Roch\u00e9 H (2018) Acute generalized exanthematous pustulosis induced by docetaxel and recurrent with letrozole: a case report. Clin Breast Cancer 18(5):e743\u2013e746. https:\/\/doi.org\/10.1016\/j.clbc.2018.06.009","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"8859_CR39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.therap.2016.12.009","volume":"72","author":"S Negrini","year":"2017","unstructured":"Negrini S, Becquemont L (2017) Pharmacogenetics of hypersensitivity drug reactions. Therapie 72(2):231\u2013243. https:\/\/doi.org\/10.1016\/j.therap.2016.12.009","journal-title":"Therapie"},{"issue":"7","key":"8859_CR40","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/1346-8138.13430","volume":"43","author":"WH Chung","year":"2016","unstructured":"Chung WH, Wang CW, Dao RL (2016) Severe cutaneous adverse drug reactions. J Dermatol 43(7):758\u2013766. https:\/\/doi.org\/10.1111\/1346-8138.13430","journal-title":"J Dermatol"},{"issue":"1","key":"8859_CR41","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.tips.2016.11.003","volume":"38","author":"A Alfirevic","year":"2017","unstructured":"Alfirevic A, Pirmohamed M (2017) Genomics of adverse drug reactions. Trends Pharmacol Sci 38(1):100\u2013109. https:\/\/doi.org\/10.1016\/j.tips.2016.11.003","journal-title":"Trends Pharmacol Sci"},{"key":"8859_CR42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.seizure.2018.06.024","volume":"60","author":"Y Deng","year":"2018","unstructured":"Deng Y, Li S, Zhang L, Jin H, Zou X (2018) Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis. Seizure 60:163\u2013171. https:\/\/doi.org\/10.1016\/j.seizure.2018.06.024","journal-title":"Seizure"},{"key":"8859_CR43","doi-asserted-by":"publisher","first-page":"5376476","DOI":"10.1155\/2018\/5376476","volume":"2018","author":"CY Ng","year":"2018","unstructured":"Ng CY, Chen CB, Wu MY, Wu J, Yang CH, Hui RC, Chang YC, Lu CW (2018) Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies. J Immunol Res 2018:5376476. https:\/\/doi.org\/10.1155\/2018\/5376476","journal-title":"J Immunol Res"},{"issue":"7559","key":"8859_CR44","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature14452","volume":"523","author":"N Gagliani","year":"2015","unstructured":"Gagliani N, Amezcua Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Lim\u00f3n P, Paiva RS, Ching T, Weaver C, Zi X, Pan X, Fan R, Garmire LX, Cotton MJ, Drier Y, Bernstein B, Geginat J, Stockinger B, Esplugues E, Huber S, Flavell RA (2015) Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 523(7559):221\u2013225. https:\/\/doi.org\/10.1038\/nature14452","journal-title":"Nature"},{"issue":"2","key":"8859_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/14740338.2017.1270940","volume":"16","author":"T Shiohara","year":"2017","unstructured":"Shiohara T, Kano Y (2017) Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin Drug Saf 16(2):139\u2013147. https:\/\/doi.org\/10.1080\/14740338.2017.1270940","journal-title":"Expert Opin Drug Saf"},{"key":"8859_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12948-017-0062-7","volume":"15","author":"GG Riario Sforza","year":"2017","unstructured":"Riario Sforza GG, Marinou A (2017) Hypersensitivity pneumonitis: a complex lung disease. Clinical and molecular allergy\u202f: CMA 15:6. https:\/\/doi.org\/10.1186\/s12948-017-0062-7","journal-title":"Clinical and molecular allergy : CMA"},{"issue":"11","key":"8859_CR47","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102(11):4134\u20134139. https:\/\/doi.org\/10.1073\/pnas.0409500102","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"8859_CR48","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/jid.2013.44","volume":"133","author":"AA Navarini","year":"2013","unstructured":"Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, Roujeau JC, Sekula P, Simpson MA, Trembath RC, Mockenhaupt M, Smith CH (2013) Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol 133(7):1904\u20131907. https:\/\/doi.org\/10.1038\/jid.2013.44","journal-title":"J Invest Dermatol"},{"issue":"6","key":"8859_CR49","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","volume":"128","author":"TM Ko","year":"2011","unstructured":"Ko TM, Chung WH, Wei CY, Shih HY, Chen JK, Lin CH, Chen YT, Hung SI (2011) Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 128(6):1266-1276.e1211. https:\/\/doi.org\/10.1016\/j.jaci.2011.08.013","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"8859_CR50","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/jid.2015.165","volume":"135","author":"WH Chung","year":"2015","unstructured":"Chung WH, Pan RY, Chu MT, Chin SW, Huang YL, Wang WC, Chang JY, Hung SI (2015) Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions. J Invest Dermatol 135(9):2237\u20132248. https:\/\/doi.org\/10.1038\/jid.2015.165","journal-title":"J Invest Dermatol"},{"key":"8859_CR51","doi-asserted-by":"publisher","first-page":"565320","DOI":"10.1155\/2014\/565320","volume":"2014","author":"CY Cheng","year":"2014","unstructured":"Cheng CY, Su SC, Chen CH, Chen WL, Deng ST, Chung WH (2014) HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review. J Immunol Res 2014:565320. https:\/\/doi.org\/10.1155\/2014\/565320","journal-title":"J Immunol Res"},{"issue":"5","key":"8859_CR52","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jama.2014.7859","volume":"312","author":"WH Chung","year":"2014","unstructured":"Chung WH, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, Chen MJ, Lin JY, Hui RC, Ho JC, Wu WM, Chen TJ, Wu T, Wu YR, Hsih MS, Tu PH, Chang CN, Hsu CN, Wu TL, Choon SE, Hsu CK, Chen DY, Liu CS, Lin CY, Kaniwa N, Saito Y, Takahashi Y, Nakamura R, Azukizawa H, Shi Y, Wang TH, Chuang SS, Tsai SF, Chang CJ, Chang YS, Hung SI (2014) Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312(5):525\u2013534. https:\/\/doi.org\/10.1001\/jama.2014.7859","journal-title":"JAMA"},{"issue":"6","key":"8859_CR53","doi-asserted-by":"publisher","first-page":"e0131038","DOI":"10.1371\/journal.pone.0131038","volume":"10","author":"P Nicoletti","year":"2015","unstructured":"Nicoletti P, Bansal M, Lefebvre C, Guarnieri P, Shen Y, Pe\u2019er I, Califano A, Floratos A, (2015) ABC transporters and the proteasome complex are implicated in susceptibility to Stevens-Johnson syndrome and toxic epidermal necrolysis across multiple drugs. PLoS One 10(6):e0131038. https:\/\/doi.org\/10.1371\/journal.pone.0131038","journal-title":"PLoS ONE"},{"issue":"6","key":"8859_CR54","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.eplepsyres.2014.03.017","volume":"108","author":"W Wang","year":"2014","unstructured":"Wang W, Hu FY, Wu XT, An DM, Yan B, Zhou D (2014) Genetic susceptibility to the cross-reactivity of aromatic antiepileptic drugs-induced cutaneous adverse reactions. Epilepsy Res 108(6):1041\u20131045. https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.03.017","journal-title":"Epilepsy Res"},{"issue":"5","key":"8859_CR55","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.trsl.2012.12.012","volume":"161","author":"MG Neuman","year":"2013","unstructured":"Neuman MG, McKinney KK, Nanau RM, Kong V, Malkiewicz I, Mazulli T, Moussa G, Cohen LB (2013) Drug-induced severe adverse reaction enhanced by human herpes virus-6 reactivation. Translational research\u202f: the journal of laboratory and clinical medicine 161(5):430\u2013440. https:\/\/doi.org\/10.1016\/j.trsl.2012.12.012","journal-title":"Translational research : the journal of laboratory and clinical medicine"},{"issue":"2","key":"8859_CR56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","volume":"115","author":"S Bastuji-Garin","year":"2000","unstructured":"Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115(2):149\u2013153. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00061.x","journal-title":"J Invest Dermatol"},{"key":"8859_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.020","author":"LL Wang","year":"2020","unstructured":"Wang LL, Noe MH, Micheletti RG (2020) Long-term sequelae from Stevens-Johnson syndrome \/ toxic epidermal necrolysis in a large retrospective cohort. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.020","journal-title":"J Am Acad Dermatol"},{"key":"8859_CR58","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.4664","author":"SB Lian","year":"2020","unstructured":"Lian SB, Oh CC, Yeo YW, Lee HY (2020) Spectrum of nail sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2020.4664","journal-title":"JAMA Dermatol"},{"key":"8859_CR59","doi-asserted-by":"publisher","unstructured":"Lefaucheur JP, Valeyrie-Allanore L, Ng Wing Tin S, Abgrall G, Colin A, Hajj C, de Prost N, Wolkenstein P, Ingen-Housz-Oro S, Chosidow O (2020) Chronic pain: a long-term sequela of epidermal necrolysis (Stevens-Johnson syndrome\/toxic epidermal necrolysis) - prevalence, clinical characteristics and risk factors. J Eur Acad Dermatol Venereol: JEADV. https:\/\/doi.org\/10.1111\/jdv.16891","DOI":"10.1111\/jdv.16891"},{"issue":"8","key":"8859_CR60","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1111\/1346-8138.14821","volume":"46","author":"J Yang","year":"2019","unstructured":"Yang J, Wang G, Fu M (2019) Drug reaction with eosinophilia and systemic symptoms presenting as leukoencephalopathy. J Dermatol 46(8):e305\u2013e307. https:\/\/doi.org\/10.1111\/1346-8138.14821","journal-title":"J Dermatol"},{"key":"8859_CR61","doi-asserted-by":"publisher","unstructured":"Vela JI, Bulnes V, Torrell N, Gir\u00f3 M, Perich S (2020) Bilateral marginal corneal infiltrates: a novel ocular manifestation of DRESS syndrome. Ocul Immunol Inflamm:1\u20133. https:\/\/doi.org\/10.1080\/09273948.2020.1797111","DOI":"10.1080\/09273948.2020.1797111"},{"key":"8859_CR62","doi-asserted-by":"publisher","unstructured":"Kano Y, Ishida T, Hirahara K, Shiohara T (2010) Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome.\u00a0Med Clin\u00a0North\u00a0Am\u00a094(4):743\u2013759, xi. https:\/\/doi.org\/10.1016\/j.mcna.2010.03.004","DOI":"10.1016\/j.mcna.2010.03.004"},{"key":"8859_CR63","doi-asserted-by":"publisher","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeau JC (2013) Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.\u00a0Br J Dermatol 169(5):1071\u20131080. https:\/\/doi.org\/10.1111\/bjd.12501","DOI":"10.1111\/bjd.12501"},{"issue":"5","key":"8859_CR64","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/pde.14217","volume":"37","author":"P Hollingsworth","year":"2020","unstructured":"Hollingsworth P, Paci K, Evans M, Miedema J, Morrell DS (2020) Alopecia universalis after drug reaction with eosinophilia and systemic symptoms (Dress). Pediatr Dermatol 37(5):947\u2013949. https:\/\/doi.org\/10.1111\/pde.14217","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"8859_CR65","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/s1085-5629(96)80038-1","volume":"15","author":"H Bocquet","year":"1996","unstructured":"Bocquet H, Bagot M, Roujeau JC (1996) Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 15(4):250\u2013257. https:\/\/doi.org\/10.1016\/s1085-5629(96)80038-1","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"8859_CR66","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1590\/s0365-05962012000300013","volume":"87","author":"PR Criado","year":"2012","unstructured":"Criado PR, Criado RF, Avancini JM, Santi CG (2012) Drug reaction with eosinophilia and systemic symptoms (DRESS) \/ drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol 87(3):435\u2013449. https:\/\/doi.org\/10.1590\/s0365-05962012000300013","journal-title":"An Bras Dermatol"},{"issue":"3","key":"8859_CR67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","volume":"28","author":"A Sidoroff","year":"2001","unstructured":"Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC (2001) Acute generalized exanthematous pustulosis (AGEP)\u2013a clinical reaction pattern. J Cutan Pathol 28(3):113\u2013119. https:\/\/doi.org\/10.1034\/j.1600-0560.2001.028003113.x","journal-title":"J Cutan Pathol"},{"issue":"6","key":"8859_CR68","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/bjd.12502","volume":"169","author":"C Hotz","year":"2013","unstructured":"Hotz C, Valeyrie-Allanore L, Haddad C, Bouvresse S, Ortonne N, Duong TA, Ingen-Housz-Oro S, Roujeau JC, Wolkenstein P, Chosidow O (2013) Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol 169(6):1223\u20131232. https:\/\/doi.org\/10.1111\/bjd.12502","journal-title":"Br J Dermatol"},{"issue":"3","key":"8859_CR69","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2340\/00015555-0616","volume":"89","author":"R Treudler","year":"2009","unstructured":"Treudler R, Grunewald S, Gebhardt C, Simon JC (2009) Prolonged course of acute generalized exanthematous pustulosis with liver involvement due to sensitization to amoxicillin and paracetamol. Acta Derm Venereol 89(3):314\u2013315. https:\/\/doi.org\/10.2340\/00015555-0616","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"8859_CR70","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4037\/ajcc2013987","volume":"22","author":"GR Mohyuddin","year":"2013","unstructured":"Mohyuddin GR, Al Asad M, Scratchko L, Khaleeq G (2013) Acute generalized exanthematous pustulosis with multiple organ dysfunction syndrome. American journal of critical care\u202f: an official publication, American Association of Critical-Care Nurses 22(3):270\u2013273. https:\/\/doi.org\/10.4037\/ajcc2013987","journal-title":"American journal of critical care : an official publication, American Association of Critical-Care Nurses"},{"issue":"4","key":"8859_CR71","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000246163","volume":"194","author":"I Eeckhout","year":"1997","unstructured":"Eeckhout I, Noens L, Ongenae K, al Sarraf Z, Schelfhout A, Naeyaert JM, (1997) Acute generalized exanthematic pustulosis: a case with a lymphoma-like presentation. Dermatology (Basel, Switzerland) 194(4):408\u2013410. https:\/\/doi.org\/10.1159\/000246163","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"2","key":"8859_CR72","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","volume":"209","author":"JC Roujeau","year":"2005","unstructured":"Roujeau JC (2005) Clinical heterogeneity of drug hypersensitivity. Toxicology 209(2):123\u2013129. https:\/\/doi.org\/10.1016\/j.tox.2004.12.022","journal-title":"Toxicology"},{"key":"8859_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.024","author":"MA Hadavand","year":"2020","unstructured":"Hadavand MA, Kaffenberger B, Cartron AM, Trinidad JC (2020) Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis (AGEP). J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.024","journal-title":"J Am Acad Dermatol"},{"key":"8859_CR74","doi-asserted-by":"publisher","unstructured":"Selvan S, Shakir R, Chan A (2013) Pustular vasculitis BMJ Case Reports.\u00a0https:\/\/doi.org\/10.1136\/bcr-2013-008806","DOI":"10.1136\/bcr-2013-008806"},{"issue":"5","key":"8859_CR75","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jaad.2016.12.024","volume":"76","author":"DY Hsu","year":"2017","unstructured":"Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI (2017) Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol 76(5):811-817.e814. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.024","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"8859_CR76","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/pde.14044","volume":"37","author":"L Metterle","year":"2020","unstructured":"Metterle L, Hatch L, Seminario-Vidal L (2020) Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature. Pediatr Dermatol 37(1):124\u2013129. https:\/\/doi.org\/10.1111\/pde.14044","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"8859_CR77","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaip.2017.02.013","volume":"5","author":"E Dibek Misirlioglu","year":"2017","unstructured":"Dibek Misirlioglu E, Guvenir H, Bahceci S, Haktanir Abul M, Can D, Usta Guc BE, Erkoco\u011flu M, Toyran M, Nacaroglu HT, Civelek E, Buyuktiryaki B, Ginis T, Orhan F, Kocabas CN (2017) Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study. J Allergy Clin Immunol Pract 5(3):757\u2013763. https:\/\/doi.org\/10.1016\/j.jaip.2017.02.013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8859_CR78","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Rocha E, Blancas L, Rodr\u00edguez-Mireles K, Gaspar-L\u00f3pez A, O\u2019Farrill-Romanillos P, Amaya-Mej\u00eda A, Galindo-Pacheco L, Campos-Romero F, Aguilar-Hinojosa N, Su\u00e1rez G (2014) Prevalence of DRESS syndrome. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 61 (1):14\u201323","DOI":"10.29262\/ram.v61i1.16"},{"issue":"5","key":"8859_CR79","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1590\/s0365-05962012000500005","volume":"87","author":"LF Botelho","year":"2012","unstructured":"Botelho LF, Higashi VS, Padilha MH, Enokihara MM, Porro AM (2012) DRESS: clinicopathological features of 10 cases from an University Hospital in S\u00e3o Paulo. An Bras Dermatol 87(5):703\u2013707. https:\/\/doi.org\/10.1590\/s0365-05962012000500005","journal-title":"An Bras Dermatol"},{"issue":"1","key":"8859_CR80","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.alit.2016.06.001","volume":"66","author":"Y Kinoshita","year":"2017","unstructured":"Kinoshita Y, Saeki H (2017) A review of toxic epidermal necrolysis management in Japan. Allergology international\u202f: official journal of the Japanese Society of Allergology 66(1):36\u201341. https:\/\/doi.org\/10.1016\/j.alit.2016.06.001","journal-title":"Allergology international : official journal of the Japanese Society of Allergology"},{"issue":"6","key":"8859_CR81","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4103\/0378-6323.191134","volume":"82","author":"LK Gupta","year":"2016","unstructured":"Gupta LK, Martin AM, Agarwal N, D\u2019Souza P, Das S, Kumar R, Pande S, Das NK, Kumaresan M, Kumar P, Garg A, Singh S (2016) Guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis: an Indian perspective. Indian J Dermatol Venereol Leprol 82(6):603\u2013625. https:\/\/doi.org\/10.4103\/0378-6323.191134","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"8859_CR82","doi-asserted-by":"publisher","unstructured":"Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, Setterfield J, Bunker CB, Ardern-Jones MR, Watson KM, Wong GA, Philippidou M, Vercueil A, Martin RV, Williams G, Shah M, Brown D, Williams P, Mohd Mustapa MF, Smith CH (2016) U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016. Br J Dermatol 174 (6):1194\u20131227.\u00a0https:\/\/doi.org\/10.1111\/bjd.14530","DOI":"10.1111\/bjd.14530"},{"issue":"1","key":"8859_CR83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12016-013-8369-8","volume":"47","author":"E Macy","year":"2014","unstructured":"Macy E, Ngor E (2014) Recommendations for the management of beta-lactam intolerance. Clin Rev Allergy Immunol 47(1):46\u201355. https:\/\/doi.org\/10.1007\/s12016-013-8369-8","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"8859_CR84","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","volume":"54","author":"M Lerch","year":"2018","unstructured":"Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T (2018) Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol 54(1):147\u2013176. https:\/\/doi.org\/10.1007\/s12016-017-8654-z","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"8859_CR85","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/bjd.12488","volume":"169","author":"J Chanal","year":"2013","unstructured":"Chanal J, Ingen-Housz-Oro S, Ortonne N, Duong TA, Thomas M, Valeyrie-Allanore L, Lebrun-Vignes B, Andr\u00e9 C, Roujeau JC, Chosidow O, Wolkenstein P (2013) Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol 169(5):1041\u20131048. https:\/\/doi.org\/10.1111\/bjd.12488","journal-title":"Br J Dermatol"},{"key":"8859_CR86","doi-asserted-by":"publisher","unstructured":"Husain Z, Reddy BY, Schwartz RA (2013) DRESS syndrome: Part II. Management and therapeutics.\u00a0J Am Acad Dermatol 68 (5):709.e701\u2013709; quiz 718\u2013720. https:\/\/doi.org\/10.1016\/j.jaad.2013.01.032","DOI":"10.1016\/j.jaad.2013.01.032"},{"issue":"2","key":"8859_CR87","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/infdis\/125.2.129","volume":"125","author":"ME Melish","year":"1972","unstructured":"Melish ME, Glasgow LA, Turner MD (1972) The staphylococcal scalded-skin syndrome: isolation and partial characterization of the exfoliative toxin. J Infect Dis 125(2):129\u2013140. https:\/\/doi.org\/10.1093\/infdis\/125.2.129","journal-title":"J Infect Dis"},{"issue":"4","key":"8859_CR88","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jtv.2014.05.001","volume":"23","author":"J Rothenberger","year":"2014","unstructured":"Rothenberger J, Krauss S, Held M, Bender D, Schaller HE, Rahmanian-Schwarz A, Constantinescu MA, Jaminet P (2014) A quantitative analysis of microcirculation in sore-prone pressure areas on conventional and pressure relief hospital mattresses using laser Doppler flowmetry and tissue spectrophotometry. J Tissue Viability 23(4):129\u2013136. https:\/\/doi.org\/10.1016\/j.jtv.2014.05.001","journal-title":"J Tissue Viability"},{"key":"8859_CR89","doi-asserted-by":"publisher","unstructured":"Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, Mozingo DW, Yowler CJ, Sheridan RL, Ahrenholz DH, Caruso DM, Foster KN, Kagan RJ, Voigt DW, Purdue GF, Hunt JL, Wolf S, Molitor F (2002) A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century.\u00a0J\u00a0Burn\u00a0Care\u00a0Rehabil\u00a023(2):87\u201396. https:\/\/doi.org\/10.1097\/00004630-200203000-00004","DOI":"10.1097\/00004630-200203000-00004"},{"issue":"4","key":"8859_CR90","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/sj.jid.5700648","volume":"127","author":"K Stur","year":"2007","unstructured":"Stur K, Karlhofer FM, Stingl G (2007) Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 127(4):802\u2013807. https:\/\/doi.org\/10.1038\/sj.jid.5700648","journal-title":"J Invest Dermatol"},{"issue":"2","key":"8859_CR91","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"C Lonjou","year":"2008","unstructured":"Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18(2):99\u2013107. https:\/\/doi.org\/10.1097\/FPC.0b013e3282f3ef9c","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"8859_CR92","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","volume":"119","author":"L Le Cleach","year":"2000","unstructured":"Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, Roujeau JC (2000) Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 119(1):225\u2013230. https:\/\/doi.org\/10.1046\/j.1365-2249.2000.01119.x","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"8859_CR93","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/cup.12894","volume":"44","author":"I Tocco-Tussardi","year":"2017","unstructured":"Tocco-Tussardi I, Huss F, Presman B (2017) Microbiological findings and antibacterial therapy in Stevens-Johnson syndrome\/toxic epidermal necrolysis patients from a Swedish Burn Center. J Cutan Pathol 44(5):420\u2013432. https:\/\/doi.org\/10.1111\/cup.12894","journal-title":"J Cutan Pathol"},{"issue":"3","key":"8859_CR94","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/bf02771767","volume":"13","author":"P Mathelier-Fusade","year":"1995","unstructured":"Mathelier-Fusade P, Leynadier F (1995) The management of adverse drug reactions. Clin Rev Allergy Immunol 13(3):281\u2013290. https:\/\/doi.org\/10.1007\/bf02771767","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2 Pt 1","key":"8859_CR95","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/s0190-9622(87)70051-6","volume":"16","author":"N Birchall","year":"1987","unstructured":"Birchall N, Langdon R, Cuono C, McGuire J (1987) Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin. J Am Acad Dermatol 16(2 Pt 1):368\u2013372. https:\/\/doi.org\/10.1016\/s0190-9622(87)70051-6","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"8859_CR96","first-page":"2171","volume":"257","author":"DM Heimbach","year":"1987","unstructured":"Heimbach DM, Engrav LH, Marvin JA, Harnar TJ, Grube BJ (1987) Toxic epidermal necrolysis. A step forward in treatment Jama 257(16):2171\u20132175","journal-title":"A step forward in treatment Jama"},{"issue":"5","key":"8859_CR97","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2230.1987.tb02508.x","volume":"12","author":"AW Macfarlane","year":"1987","unstructured":"Macfarlane AW, Curley RK (1987) Management of toxic epidermal necrolysis with a hydrogel dressing and fluidized-bead bed: report of three cases. Clin Exp Dermatol 12(5):354\u2013356. https:\/\/doi.org\/10.1111\/j.1365-2230.1987.tb02508.x","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"8859_CR98","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/00005373-198610000-00016","volume":"26","author":"JK Prasad","year":"1986","unstructured":"Prasad JK, Feller I, Thomson PD (1986) Use of amnion for the treatment of Stevens-Johnson syndrome. J Trauma 26(10):945\u2013946. https:\/\/doi.org\/10.1097\/00005373-198610000-00016","journal-title":"J Trauma"},{"issue":"11","key":"8859_CR99","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/s0161-6420(95)30811-1","volume":"102","author":"WJ Power","year":"1995","unstructured":"Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS (1995) Analysis of the acute ophthalmic manifestations of the erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis disease spectrum. Ophthalmology 102(11):1669\u20131676. https:\/\/doi.org\/10.1016\/s0161-6420(95)30811-1","journal-title":"Ophthalmology"},{"key":"8859_CR100","doi-asserted-by":"publisher","first-page":"102454","DOI":"10.1016\/j.jaut.2020.102454","volume":"111","author":"C Anquetil","year":"2020","unstructured":"Anquetil C, Salem JE, Lebrun-Vignes B, Touhami S, Desbois AC, Maalouf G, Domont F, Allenbach Y, Cacoub P, Bodaghi B, Saadoun D (2020) Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO\u2019s pharmacovigilance database. J Autoimmun 111:102454. https:\/\/doi.org\/10.1016\/j.jaut.2020.102454","journal-title":"J Autoimmun"},{"key":"8859_CR101","doi-asserted-by":"publisher","unstructured":"Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS (2005) Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 94 (4):419\u2013436; quiz 436\u2013418, 456.\u00a0https:\/\/doi.org\/10.1016\/s1081-1206(10)61112-x","DOI":"10.1016\/s1081-1206(10)61112-x"},{"issue":"4","key":"8859_CR102","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4037\/ccn2013555","volume":"33","author":"B Seczynska","year":"2013","unstructured":"Seczynska B, Nowak I, Sega A, Kozka M, Wodkowski M, Kr\u00f3likowski W, Szczeklik W (2013) Supportive therapy for a patient with toxic epidermal necrolysis undergoing plasmapheresis. Crit Care Nurse 33(4):26\u201338. https:\/\/doi.org\/10.4037\/ccn2013555","journal-title":"Crit Care Nurse"},{"issue":"6","key":"8859_CR103","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","volume":"16","author":"RP Dodiuk-Gad","year":"2015","unstructured":"Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH (2015) Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol 16(6):475\u2013493. https:\/\/doi.org\/10.1007\/s40257-015-0158-0","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"8859_CR104","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/bjd.14799","volume":"175","author":"RP Dodiuk-Gad","year":"2016","unstructured":"Dodiuk-Gad RP, Olteanu C, Feinstein A, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, Finkelstein Y, Burnett M, Sade S, Cartotto R, Jeschke M, Shear NH (2016) Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 175(2):422\u2013424. https:\/\/doi.org\/10.1111\/bjd.14799","journal-title":"Br J Dermatol"},{"key":"8859_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","volume":"92","author":"R Cervera","year":"2018","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I, Espinosa G (2018) The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun 92:1\u201311. https:\/\/doi.org\/10.1016\/j.jaut.2018.05.007","journal-title":"J Autoimmun"},{"issue":"1","key":"8859_CR106","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/archderm.1994.01690010122026","volume":"130","author":"B Moncada","year":"1994","unstructured":"Moncada B, Delgado C, Quevedo ME, Lorincz AL (1994) Abnormal T-cell response in toxic epidermal necrolysis. Arch Dermatol 130(1):116\u2013117","journal-title":"Arch Dermatol"},{"key":"8859_CR107","doi-asserted-by":"publisher","first-page":"928910","DOI":"10.1155\/2013\/928910","volume":"2013","author":"C Kocaoglu","year":"2013","unstructured":"Kocaoglu C, Cilasun C, Solak ES, Kurtipek GS, Arslan S (2013) Successful treatment of antiepileptic drug-induced DRESS syndrome with pulse methylprednisolone. Case reports in pediatrics 2013:928910. https:\/\/doi.org\/10.1155\/2013\/928910","journal-title":"Case reports in pediatrics"},{"issue":"6","key":"8859_CR108","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.mayocp.2016.03.006","volume":"91","author":"TJ Bommersbach","year":"2016","unstructured":"Bommersbach TJ, Lapid MI, Leung JG, Cunningham JL, Rummans TA, Kung S (2016) Management of psychotropic drug-induced DRESS syndrome: a systematic review. Mayo Clin Proc 91(6):787\u2013801. https:\/\/doi.org\/10.1016\/j.mayocp.2016.03.006","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"8859_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2332\/allergolint.55.1","volume":"55","author":"T Shiohara","year":"2006","unstructured":"Shiohara T, Inaoka M, Kano Y (2006) Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergology international\u202f: official journal of the Japanese Society of Allergology 55(1):1\u20138. https:\/\/doi.org\/10.2332\/allergolint.55.1","journal-title":"Allergology international : official journal of the Japanese Society of Allergology"},{"key":"8859_CR110","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1471-2334-10-49","volume":"10","author":"I Gentile","year":"2010","unstructured":"Gentile I, Talamo M, Borgia G (2010) Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review. BMC Infect Dis 10:49. https:\/\/doi.org\/10.1186\/1471-2334-10-49","journal-title":"BMC Infect Dis"},{"issue":"6","key":"8859_CR111","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1684\/ejd.2011.1550","volume":"21","author":"CH Wei","year":"2011","unstructured":"Wei CH, Chung-Yee Hui R, Chang CJ, Ho HC, Yang CH, Lin YJ, Chung WH (2011) Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol: EJD 21(6):930\u2013937. https:\/\/doi.org\/10.1684\/ejd.2011.1550","journal-title":"Eur J Dermatol: EJD"},{"issue":"2","key":"8859_CR112","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaad.2009.08.050","volume":"63","author":"CC Ang","year":"2010","unstructured":"Ang CC, Wang YS, Yoosuff EL, Tay YK (2010) Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol 63(2):219\u2013227. https:\/\/doi.org\/10.1016\/j.jaad.2009.08.050","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"8859_CR113","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.autrev.2015.12.006","volume":"15","author":"G Iannella","year":"2016","unstructured":"Iannella G, Greco A, Didona D, Didona B, Granata G, Manno A, Pasquariello B, Magliulo G (2016) Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 15(4):335\u2013343. https:\/\/doi.org\/10.1016\/j.autrev.2015.12.006","journal-title":"Autoimmun Rev"},{"issue":"6","key":"8859_CR114","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/archderm.1995.01690180043007","volume":"131","author":"F Guibal","year":"1995","unstructured":"Guibal F, Bastuji-Garin S, Chosidow O, Saiag P, Revuz J, Roujeau JC (1995) Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 131(6):669\u2013672","journal-title":"Arch Dermatol"},{"key":"8859_CR115","doi-asserted-by":"publisher","unstructured":"Sherertz EF, Jegasothy BV, Lazarus GS (1985) Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid \u201cpulse therapy\u201d.\u00a0J Am Acad Dermatol 12(1 Pt 2):178\u2013181. https:\/\/doi.org\/10.1016\/s0190-9622(85)80012-8","DOI":"10.1016\/s0190-9622(85)80012-8"},{"issue":"5","key":"8859_CR116","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","volume":"204","author":"PH Halebian","year":"1986","unstructured":"Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT (1986) Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 204(5):503\u2013512. https:\/\/doi.org\/10.1097\/00000658-198611000-00001","journal-title":"Ann Surg"},{"issue":"2","key":"8859_CR117","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12016-015-8491-x","volume":"50","author":"M Kuruvilla","year":"2016","unstructured":"Kuruvilla M, Khan DA (2016) Eosinophilic drug allergy. Clin Rev Allergy Immunol 50(2):228\u2013239. https:\/\/doi.org\/10.1007\/s12016-015-8491-x","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"8859_CR118","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaip.2013.11.008","volume":"2","author":"VR Galv\u00e3o","year":"2014","unstructured":"Galv\u00e3o VR, Aun MV, Kalil J, Castells M, Giavina-Bianchi P (2014) Clinical and laboratory improvement after intravenous immunoglobulin in drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol Pract 2(1):107\u2013110. https:\/\/doi.org\/10.1016\/j.jaip.2013.11.008","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"8859_CR119","doi-asserted-by":"publisher","first-page":"506","DOI":"10.4103\/0378-6323.113080","volume":"79","author":"S Jagadeesan","year":"2013","unstructured":"Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ravindran S, Divakaran MV, Skaria L, Kurien G (2013) Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian J Dermatol Venereol Leprol 79(4):506\u2013511. https:\/\/doi.org\/10.4103\/0378-6323.113080","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"8859_CR120","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1097\/BCR.0b013e318254d2ec","volume":"33","author":"QY Zhu","year":"2012","unstructured":"Zhu QY, Ma L, Luo XQ, Huang HY (2012) Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. Journal of burn care & research\u202f: official publication of the American Burn Association 33(6):e295-308. https:\/\/doi.org\/10.1097\/BCR.0b013e318254d2ec","journal-title":"Journal of burn care & research : official publication of the American Burn Association"},{"issue":"6","key":"8859_CR121","first-page":"679","volume":"12","author":"DJ Aires","year":"2013","unstructured":"Aires DJ, Fraga G, Korentager R, Richie CP, Aggarwal S, Wick J, Liu DY (2013) Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol: JDD 12(6):679\u2013684","journal-title":"J Drugs Dermatol: JDD"},{"issue":"1","key":"8859_CR122","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archderm.139.1.26","volume":"139","author":"C Prins","year":"2003","unstructured":"Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE (2003) Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139(1):26\u201332. https:\/\/doi.org\/10.1001\/archderm.139.1.26","journal-title":"Arch Dermatol"},{"issue":"6","key":"8859_CR123","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/bjd.12607","volume":"169","author":"HY Lee","year":"2013","unstructured":"Lee HY, Lim YL, Thirumoorthy T, Pang SM (2013) The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol 169(6):1304\u20131309. https:\/\/doi.org\/10.1111\/bjd.12607","journal-title":"Br J Dermatol"},{"issue":"6","key":"8859_CR124","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","volume":"153","author":"S Zimmermann","year":"2017","unstructured":"Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M (2017) Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 153(6):514\u2013522. https:\/\/doi.org\/10.1001\/jamadermatol.2016.5668","journal-title":"JAMA Dermatol"},{"issue":"5388","key":"8859_CR125","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (New York, NY) 282(5388):490\u2013493. https:\/\/doi.org\/10.1126\/science.282.5388.490","journal-title":"Science (New York, NY)"},{"issue":"5","key":"8859_CR126","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","volume":"130","author":"P Paquet","year":"1994","unstructured":"Paquet P, Nikkels A, Arrese JE, Vanderkelen A, Pi\u00e9rard GE (1994) Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 130(5):605\u2013608","journal-title":"Arch Dermatol"},{"issue":"4","key":"8859_CR127","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","volume":"163","author":"L Valeyrie-Allanore","year":"2010","unstructured":"Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Ma\u00eetre B, Revuz J, Bagot M, Roujeau JC (2010) Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163(4):847\u2013853. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09863.x","journal-title":"Br J Dermatol"},{"issue":"5","key":"8859_CR128","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","volume":"71","author":"MG Kirchhof","year":"2014","unstructured":"Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP (2014) Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol 71(5):941\u2013947. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"8859_CR129","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5414\/cnp64155","volume":"64","author":"E Zuliani","year":"2005","unstructured":"Zuliani E, Zwahlen H, Gilliet F, Marone C (2005) Vancomycin-induced hypersensitivity reaction with acute renal failure: resolution following cyclosporine treatment. Clin Nephrol 64(2):155\u2013158. https:\/\/doi.org\/10.5414\/cnp64155","journal-title":"Clin Nephrol"},{"issue":"6","key":"8859_CR130","doi-asserted-by":"publisher","first-page":"713","DOI":"10.4103\/ijdvl.IJDVL_1084_16","volume":"83","author":"ZX Zhang","year":"2017","unstructured":"Zhang ZX, Yang BQ, Yang Q, Wu M, Wang GJ (2017) Treatment of drug-induced hypersensitivity syndrome with cyclosporine. Indian J Dermatol Venereol Leprol 83(6):713\u2013717. https:\/\/doi.org\/10.4103\/ijdvl.IJDVL_1084_16","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"11","key":"8859_CR131","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1001\/jamadermatol.2016.2220","volume":"152","author":"MG Kirchhof","year":"2016","unstructured":"Kirchhof MG, Wong A, Dutz JP (2016) Cyclosporine treatment of drug-induced hypersensitivity syndrome. JAMA Dermatol 152(11):1254\u20131257. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2220","journal-title":"JAMA Dermatol"},{"issue":"6","key":"8859_CR132","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s12325-017-0530-y","volume":"34","author":"JA Schneider","year":"2017","unstructured":"Schneider JA, Cohen PR (2017) Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther 34(6):1235\u20131244. https:\/\/doi.org\/10.1007\/s12325-017-0530-y","journal-title":"Adv Ther"},{"issue":"3","key":"8859_CR133","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/s0190-9622(99)70497-4","volume":"40","author":"CA Egan","year":"1999","unstructured":"Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ (1999) Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 40(3):458\u2013461. https:\/\/doi.org\/10.1016\/s0190-9622(99)70497-4","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"8859_CR134","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1177\/039139889101401006","volume":"14","author":"G Sakellariou","year":"1991","unstructured":"Sakellariou G, Koukoudis P, Karpouzas J, Alexopoulos E, Papadopoulou D, Chrisomalis F, Skenteris N, Tsakaris D, Papadimitriou M (1991) Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs 14(10):634\u2013638","journal-title":"Int J Artif Organs"},{"issue":"12","key":"8859_CR135","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","volume":"121","author":"D Kamanabroo","year":"1985","unstructured":"Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM (1985) Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 121(12):1548\u20131549","journal-title":"Arch Dermatol"},{"key":"8859_CR136","doi-asserted-by":"publisher","unstructured":"Konstantinow A, M\u00fchlbauer W, Balda BR, Ring J (2001) [Toxic epidermal necrolysis (drug-induced Lyell\u2019s syndrome). 2. Treatment]. Deutsche medizinische Wochenschrift (1946) 126(7):177\u2013179. https:\/\/doi.org\/10.1055\/s-2001-11190","DOI":"10.1055\/s-2001-11190"},{"issue":"3","key":"8859_CR137","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1346-8138.2010.01154.x","volume":"38","author":"YM Narita","year":"2011","unstructured":"Narita YM, Hirahara K, Mizukawa Y, Kano Y, Shiohara T (2011) Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol 38(3):236\u2013245. https:\/\/doi.org\/10.1111\/j.1346-8138.2010.01154.x","journal-title":"J Dermatol"},{"issue":"2","key":"8859_CR138","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/ijd.13837","volume":"57","author":"RA El-Azhary","year":"2018","unstructured":"El-Azhary RA, Wang MZ, Wentworth AB, Hickson LJ (2018) Treatment of severe drug reactions by hemodialysis. Int J Dermatol 57(2):177\u2013182. https:\/\/doi.org\/10.1111\/ijd.13837","journal-title":"Int J Dermatol"},{"issue":"11","key":"8859_CR139","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s001340051063","volume":"25","author":"A Furubacke","year":"1999","unstructured":"Furubacke A, Berlin G, Anderson C, Sj\u00f6berg F (1999) Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med 25(11):1307\u20131310. https:\/\/doi.org\/10.1007\/s001340051063","journal-title":"Intensive Care Med"},{"issue":"2","key":"8859_CR140","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1097\/gox.0000000000001221","volume":"5","author":"G Giudice","year":"2017","unstructured":"Giudice G, Maggio G, Bufano L, Memeo G, Vestita M (2017) Management of toxic epidermal necrolysis with plasmapheresis and cyclosporine A: our 10 years\u2019 experience. Plast Reconstr Surg Glob Open 5(2):e1221. https:\/\/doi.org\/10.1097\/gox.0000000000001221","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"3","key":"8859_CR141","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1006\/clin.1996.0181","volume":"81","author":"JD Klausner","year":"1996","unstructured":"Klausner JD, Freedman VH, Kaplan G (1996) Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 81(3):219\u2013223. https:\/\/doi.org\/10.1006\/clin.1996.0181","journal-title":"Clin Immunol Immunopathol"},{"issue":"9140","key":"8859_CR142","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/s0140-6736(98)02197-7","volume":"352","author":"P Wolkenstein","year":"1998","unstructured":"Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet (London, England) 352(9140):1586\u20131589. https:\/\/doi.org\/10.1016\/s0140-6736(98)02197-7","journal-title":"Lancet (London, England)"},{"issue":"3","key":"8859_CR143","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1053\/j.ajkd.2009.10.054","volume":"55","author":"E Laban","year":"2010","unstructured":"Laban E, Hainaut-Wierzbicka E, Pourreau F, Yacoub M, Sztermer E, Guillet G, Touchard G, Bridoux F (2010) Cyclophosphamide therapy for corticoresistant drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient with severe kidney and eye involvement and Epstein-Barr virus reactivation. Am J Kidney Dis 55(3):e11-14. https:\/\/doi.org\/10.1053\/j.ajkd.2009.10.054","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"8859_CR144","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","volume":"48","author":"JM Ar\u00e9valo","year":"2000","unstructured":"Ar\u00e9valo JM, Lorente JA, Gonz\u00e1lez-Herrada C, Jim\u00e9nez-Reyes J (2000) Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 48(3):473\u2013478. https:\/\/doi.org\/10.1097\/00005373-200003000-00017","journal-title":"J Trauma"},{"issue":"2","key":"8859_CR145","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","volume":"71","author":"A Paradisi","year":"2014","unstructured":"Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B (2014) Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol 71(2):278\u2013283. https:\/\/doi.org\/10.1016\/j.jaad.2014.04.044","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"8859_CR146","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","volume":"116","author":"RE Hunger","year":"2005","unstructured":"Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N (2005) Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 116(4):923\u2013924. https:\/\/doi.org\/10.1016\/j.jaci.2005.06.029","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"8859_CR147","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/jci93349","volume":"128","author":"CW Wang","year":"2018","unstructured":"Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, Chang CJ, Su SC, Hui RC, Chin SW, Huang LF, Lin YY, Chang WY, Fan WL, Yang CY, Ho JC, Chang YC, Lu CW, Chung WH (2018) Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Investig 128(3):985\u2013996. https:\/\/doi.org\/10.1172\/jci93349","journal-title":"J Clin Investig"},{"issue":"20","key":"8859_CR148","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376(20):1921\u20131932. https:\/\/doi.org\/10.1056\/NEJMoa1702079","journal-title":"N Engl J Med"},{"issue":"3","key":"8859_CR149","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaip.2017.10.020","volume":"6","author":"N Ange","year":"2018","unstructured":"Ange N, Alley S, Fernando SL, Coyle L, Yun J (2018) Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome successfully treated with mepolizumab. J Allergy Clin Immunol Pract 6(3):1059\u20131060. https:\/\/doi.org\/10.1016\/j.jaip.2017.10.020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8859_CR150","doi-asserted-by":"publisher","first-page":"666","DOI":"10.12659\/ajcr.899823","volume":"17","author":"R Uzun","year":"2016","unstructured":"Uzun R, Yalcin AD, Celik B, Bulut T, Yalcin AN (2016) Levofloxacin induced toxic epidermal necrolysis: successful therapy with omalizumab (anti-IgE) and pulse prednisolone. The American journal of case reports 17:666\u2013671. https:\/\/doi.org\/10.12659\/ajcr.899823","journal-title":"The American journal of case reports"},{"issue":"4","key":"8859_CR151","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1365-2133.2009.09585.x","volume":"162","author":"A de Sica-Chapman","year":"2010","unstructured":"de Sica-Chapman A, Williams G, Soni N, Bunker CB (2010) Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol [corrected]. Br J Dermatol 162(4):860\u2013865. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09585.x","journal-title":"Br J Dermatol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08859-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-021-08859-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08859-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:53:26Z","timestamp":1744152806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-021-08859-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":151,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8859"],"URL":"https:\/\/doi.org\/10.1007\/s12016-021-08859-0","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,17]]},"assertion":[{"value":"20 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}